The Cancer Letter’s coverage of power morcellation named a finalist in the 2015 Best in Business Awards for Outstanding Business Journalism

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Matthew Ong, associate editor of The Cancer Letter, was selected as a finalist in the 2015 Best in Business Awards for Outstanding Business Journalism.

The Society of American Business Editors and Writers recognized Ong’s series, “How Medical Devices Do Harm,” as the first runner up in the Print Weeklies/Biweeklies Investigative category. In a two-year investigation, Ong examined how doctors, hospitals, and manufacturers can, as a practical matter, conceal the fact that a device has caused harm and allow adverse outcomes to go unreported. The controversy, which stemmed from an initial focus on power morcellators and FDA regulation of medical devices, has become the focus of investigations launched by Congress, FBI and the Government Accountability Office.

“The Cancer Letter’s coverage of dangerous medical devices provided an important public service by examining the problems that arise with these devices and the regulatory lapses that helped these problems develop,” the judges noted. “The Cancer Letter covered incremental developments over a lengthy period, but also took the time to step back and do necessary big-picture stories on the issue.”

Ong previously won three first place awards, from the National Press Club, the Society of Professional Journalists, and the Washington, D.C. Professional Chapter of the Society of Professional Journalists, for his 2014 coverage of the controversy over power morcellation (The Cancer Letter, July 2, 2015).

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login